

Note Regarding Presentation of Non-GAAP Financial Measures

The financial data contained in the Company's public documents may include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.

The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health ("adjusted earnings per share"). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims, windfall tax benefits, and executive compensation disallowance); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States ("GAAP") as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share below.

The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company's credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct cash on hand from consolidated total debt. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments, subject to certain limitations, resulting from (1) dispositions and repayments or incurrence of debt and (2) investments, acquisitions, mergers, amalgamations, consolidations and other operational changes to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. The Company reconciles Adjusted EBITDA to net cash provided by operating activities and to net income below.

The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company's credit agreement, which is discussed in more detail in Part II, Item 7, *Management's Discussion and Analysis of Financial Condition and Results of Operations*, "Liquidity and Capital Resources," and Note 8, *Long-term Debt*, to the consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"). These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company's lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company's existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company's assessment of its liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as "Adjusted Consolidated EBITDA," allows the Company to add back to consolidated net income interest expense, income

taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to \$10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment of debt and acquisitions, and (7) any restructuring charges and certain pro-forma cost savings and synergies related to transactions and initiatives, which in the aggregate are not in excess of 25% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.

The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of \$10 million. These items and amounts, in addition to the items falling within the credit agreement's "unusual or nonrecurring" classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company's ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, *Summary of Significant Accounting Policies*, to the consolidated financial statements accompanying the 2025 Form 10-K.

The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company's capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The reconciliation of net cash provided by operating activities to adjusted free cash flow is below. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company's definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, distributions to noncontrolling interests, and certain items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. The Company's definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2025 Form 10-K for the GAAP measures of cash flows from operating, investing, and financing activities.

For the Three Months Ended March 31, 2026

	Adjustments					As Adjusted
	As Reported	Loss on Early Exting. of Debt	Income Tax Adjustments	Change in Fair Market Value of Marketable Securities	Gain on Sale of Gamma Knife	
	(In Millions, Except Per Share Amounts)					
Adjusted EBITDA	\$ 348.8	\$ —	\$ —	\$ —	\$ —	\$ 348.8
Depreciation and amortization	(87.3)	—	—	—	—	(87.3)
Interest expense and amortization of debt discounts and fees	(31.8)	—	—	—	—	(31.8)
Stock-based compensation	(11.5)	—	—	—	—	(11.5)
Loss on disposal or impairment of assets	(0.3)	—	—	—	—	(0.3)
Loss on early extinguishment of debt	(0.2)	0.2	—	—	—	—
Change in fair market value of marketable securities	(0.2)	—	—	0.2	—	—
Gain on sale of Gamma Knife	17.5	—	—	—	(17.5)	—
Income from continuing operations before income tax expense	235.0	0.2	—	0.2	(17.5)	217.9
Provision for income tax expense	(56.4)	(0.1)	(4.7)	—	4.5	(56.7)
Income from continuing operations attributable to Encompass Health	\$ 178.6	\$ 0.1	\$ (4.7)	\$ 0.2	\$ (13.0)	\$ 161.2
Diluted earnings per share from continuing operations*	\$ 1.77	\$ —	\$ (0.05)	\$ —	\$ (0.13)	\$ 1.60
Diluted shares used in calculation	100.6					

* Adjusted EPS may not sum across due to rounding.

For the Three Months Ended March 31, 2025

	Adjustments			
	As Reported	Income Tax Adjustments	Change in Fair Market Value of Marketable Securities	As Adjusted
	(In Millions, Except Per Share Amounts)			
Adjusted EBITDA	\$ 313.6	\$ —	\$ —	\$ 313.6
Depreciation and amortization	(79.2)	—	—	(79.2)
Interest expense and amortization of debt discounts and fees	(31.8)	—	—	(31.8)
Stock-based compensation	(9.5)	—	—	(9.5)
Loss on disposal or impairment of assets	(0.2)	—	—	(0.2)
Change in fair market value of marketable securities	0.7	—	(0.7)	—
Income from continuing operations before income tax expense	193.6	—	(0.7)	192.9
Provision for income tax expense	(41.6)	(12.0)	0.2	(53.4)
Income from continuing operations attributable to Encompass Health	\$ 152.0	\$ (12.0)	\$ (0.5)	\$ 139.5
Diluted earnings per share from continuing operations*	\$ 1.48	\$ (0.12)	\$ —	\$ 1.37
Diluted shares used in calculation	102.1			

* Adjusted EPS may not sum across due to rounding.

For the Year Ended December 31, 2025

	<u>Adjustments</u>			<u>As Adjusted</u>
	<u>As Reported</u>	<u>Income Tax Adjustments</u>	<u>Change in Fair Market Value of Marketable Securities</u>	
(In Millions, Except Per Share Amounts)				
Adjusted EBITDA	\$ 1,267.9	\$ —	\$ —	\$ 1,267.9
Depreciation and amortization	(327.9)	—	—	(327.9)
Interest expense and amortization of debt discounts and fees	(123.2)	—	—	(123.2)
Stock-based compensation	(56.5)	—	—	(56.5)
Loss on disposal or impairment of assets	(2.7)	—	—	(2.7)
Change in fair market value of marketable securities	2.5	—	(2.5)	—
Income from continuing operations before income tax expense	760.1	—	(2.5)	757.6
Provision for income tax expense	(192.9)	(7.9)	0.6	(200.2)
Income from continuing operations attributable to Encompass Health	\$ 567.2	\$ (7.9)	\$ (1.9)	\$ 557.4
Diluted earnings per share from continuing operations*	\$ 5.55	\$ (0.08)	\$ (0.02)	\$ 5.45
Diluted shares used in calculation	102.2			

* Adjusted EPS may not sum across due to rounding.

For the Year Ended December 31, 2024

	Adjustments					As Adjusted
	As Reported	Asset Impairment Impact	Loss on Early Exting. of Debt	Income Tax Adjustments	Change in Fair Market Value of Marketable Securities	
	(In Millions, Except Per Share Amounts)					
Adjusted EBITDA	\$ 1,103.7	\$ —	\$ —	\$ —	\$ —	\$ 1,103.7
Depreciation and amortization	(299.6)	—	—	—	—	(299.6)
Interest expense and amortization of debt discounts and fees	(137.4)	—	—	—	—	(137.4)
Stock-based compensation	(48.3)	—	—	—	—	(48.3)
Loss on disposal or impairment of assets	(17.4)	10.4	—	—	—	(7.0)
Loss on early extinguishment of debt	(0.6)	—	0.6	—	—	—
Change in fair market value of marketable securities	1.0	—	—	—	(1.0)	—
Asset impairment impact on noncontrolling interests	7.3	(7.3)	—	—	—	—
Income from continuing operations before income tax expense	608.7	3.1	0.6	—	(1.0)	611.4
Provision for income tax expense	(150.2)	(1.3)	(0.2)	(7.7)	0.3	(159.1)
Income from continuing operations attributable to Encompass Health	\$ 458.5	\$ 1.8	\$ 0.4	\$ (7.7)	\$ (0.7)	\$ 452.3
Diluted earnings per share from continuing operations*	\$ 4.49	\$ 0.02	\$ —	\$ (0.08)	\$ (0.01)	\$ 4.43
Diluted shares used in calculation	102.2					

* Adjusted EPS may not sum across due to rounding.

For the Year Ended December 31, 2023

	Adjustments				As Adjusted
	As Reported	State Regulatory Change Impact	Income Tax Adjustments	Change in Fair Market Value of Marketable Securities	
(In Millions, Except Per Share Amounts)					
Adjusted EBITDA	\$ 971.1	\$ —	\$ —	\$ —	\$ 971.1
Depreciation and amortization	(273.9)	6.1	—	—	(267.8)
Interest expense and amortization of debt discounts and fees	(143.5)	—	—	—	(143.5)
Stock-based compensation	(50.6)	—	—	—	(50.6)
Loss on disposal or impairment of assets	(9.8)	—	—	—	(9.8)
State regulatory change impact on noncontrolling interests	2.2	(2.2)	—	—	—
Change in fair market value of marketable securities	0.7	—	—	(0.7)	—
Income from continuing operations before income tax expense	496.2	3.9	—	(0.7)	499.4
Provision for income tax expense	(132.2)	(1.0)	2.8	0.2	(130.2)
Income from continuing operations attributable to Encompass Health	\$ 364.0	\$ 2.9	\$ 2.8	\$ (0.5)	\$ 369.2
Diluted earnings per share from continuing operations*	\$ 3.59	\$ 0.03	\$ 0.03	\$ —	\$ 3.64
Diluted shares used in calculation	101.3				

* Adjusted EPS may not sum across due to rounding.

	Three Months Ended		For the Year Ended December 31,		
	March 31,		2025	2024	2023
	2026	2025	2025	2024	2023
	(In Millions)				
Net cash provided by operating activities	\$ 313.1	\$ 288.6	\$ 1,175.6	\$ 1,002.8	\$ 850.8
Interest expense and amortization of debt discounts and fees	31.8	31.8	123.2	137.4	143.5
Gain (loss) on investments, excluding impairments	16.2	(0.1)	5.9	2.7	4.6
Equity in net income of nonconsolidated affiliates	0.4	0.9	4.3	3.0	3.2
Net income attributable to noncontrolling interests in continuing operations	(53.7)	(45.0)	(192.9)	(140.9)	(111.0)
Amortization of debt-related items	(2.4)	(2.4)	(9.6)	(9.7)	(9.5)
Distributions from nonconsolidated affiliates	(0.1)	(0.5)	(4.1)	(4.0)	(1.6)
Current portion of income tax expense	47.9	32.8	170.6	139.5	128.3
Change in assets and liabilities	33.8	7.5	(4.3)	(21.9)	(50.3)
Cash (provided by) used in operating activities of discontinued operations	(21.2)	0.7	1.4	3.1	16.0
State regulatory change impact on noncontrolling interests	—	—	—	—	(2.2)
Asset impairment impact on noncontrolling interests	—	—	—	(7.3)	—
Change in fair market value of marketable securities	0.2	(0.7)	(2.5)	(1.0)	(0.7)
Gain on sale of Gamma Knife	(17.5)	—	—	—	—
Other	0.3	—	0.3	—	—
Adjusted EBITDA	\$ 348.8	\$ 313.6	\$ 1,267.9	\$ 1,103.7	\$ 971.1

	Three Months Ended		For the Year Ended December 31,		
	March 31,				
	2026	2025	2025	2024	2023
	(In Millions)				
Net income	\$ 248.2	\$ 196.5	\$ 759.1	\$ 596.6	\$ 463.0
(Income) loss from discontinued operations, net of tax, attributable to Encompass Health	(15.9)	0.5	1.0	2.8	12.0
Net income attributable to noncontrolling interests included in continuing operations	(53.7)	(45.0)	(192.9)	(140.9)	(111.0)
Provision for income tax expense	56.4	41.6	192.9	150.2	132.2
Interest expense and amortization of debt discounts and fees	31.8	31.8	123.2	137.4	143.5
Depreciation and amortization	87.3	79.2	327.9	299.6	273.9
Loss on early extinguishment of debt	0.2	—	—	0.6	—
Loss on disposal or impairment of assets	0.3	0.2	2.7	17.4	9.8
Stock-based compensation expense	11.5	9.5	56.5	48.3	50.6
Asset impairment impact on noncontrolling interests	—	—	—	(7.3)	—
State regulatory change impact on noncontrolling interests	—	—	—	—	(2.2)
Change in fair market value of marketable securities	0.2	(0.7)	(2.5)	(1.0)	(0.7)
Gain on sale of Gamma Knife	(17.5)	—	—	—	—
Adjusted EBITDA	\$ 348.8	\$ 313.6	\$ 1,267.9	\$ 1,103.7	\$ 971.1

	Three Months Ended March 31,		For the Year Ended December 31,		
	2026	2025	2025	2024	2023
	(In Millions)				
Net cash provided by operating activities	\$ 313.1	\$ 288.6	\$ 1,175.6	\$ 1,002.8	\$ 850.8
Impact of discontinued operations	(21.2)	0.7	1.4	3.1	16.0
Net cash provided by operating activities of continuing operations	291.9	289.3	1,177.0	1,005.9	866.8
Capital expenditures for maintenance	(43.8)	(34.0)	(209.5)	(184.6)	(216.9)
Distributions paid to noncontrolling interests of consolidated affiliates	(57.8)	(32.9)	(152.1)	(125.0)	(114.7)
Items non-indicative of ongoing operations:					
Transaction costs and related assumed liabilities	3.5	—	2.5	(6.0)	(9.5)
Adjusted free cash flow	<u>\$ 193.8</u>	<u>\$ 222.4</u>	<u>\$ 817.9</u>	<u>\$ 690.3</u>	<u>\$ 525.7</u>

For the three months ended March 31, 2026, net cash used in investing activities was \$150.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2026 was \$102.5 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, and taxes paid on behalf of employees for shares withheld partially offset by net debt borrowings.

For the three months ended March 31, 2025, net cash used in investing activities was \$158.5 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2025 was \$130.4 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock.

For the year ended December 31, 2025, net cash used in investing activities was \$764.6 million and resulted primarily from capital expenditures. Net cash used in financing activities during the year ended December 31, 2025 was \$431.2 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock and net debt payments.

For the year ended December 31, 2024, net cash used in investing activities was \$653.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the year ended December 31, 2024 was \$330.6 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interest of consolidated affiliates.

For the year ended December 31, 2023, net cash used in investing activities was \$602.8 million and resulted primarily from capital expenditures. Net cash used in financing activities during the year ended December 31, 2023 was \$197.2 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, and cash dividends paid on common stock partially offset by contributions from noncontrolling interest of consolidated affiliates.